Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
methylphenidate + cannabidiol
- Development stage
- Phase 4
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination of methylphenidate (MPH), a central nervous system stimulant used primarily for treating ADHD, and cannabidiol (CBD), a non-psychoactive cannabinoid. In vitro studies have shown that CBD can inhibit carboxylesterase 1 (CES1), the enzyme responsible for metabolizing methylphenidate, suggesting a potential pharmacokinetic interaction. Clinical studies have found this interaction to be weak and likely clinically insignificant at standard therapeutic doses.
- Other names
- MPH + CBDdl-methylphenidate + cannabidiol
02
Targets
CNR1 (Cannabinoid receptor 1)CES1 (Liver carboxylesterase 1)DAT (Dopamine plasma membrane transport protein)NET (Norepinephrine Transporter)
Beyond the preview
Go deeper on methylphenidate + cannabidiol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on methylphenidate + cannabidiol.